Medical history at baseline for the US and combined cohorts
| N (%) | US cohort | Combined group cohort |
| n=100 | n=191 | |
| CVD complications | 19 (19.0) | 54 (28.3) |
| Myocardial infarction | 4 (4.0) | 16 (8.4) |
| Angina | 6 (6.0) | 25 (13.1) |
| Peripheral vascular disease | 6 (6.0) | 11 (5.8) |
| Stroke | 4 (4.0) | 9 (4.7) |
| Heart failure | 3 (3.0) | 6 (3.1) |
| Atrial fibrillation | 0 (0.0) | 5 (2.6) |
| Left ventricular hypertrophy | 1 (1.0) | 10 (5.2) |
| Renal complications | 13 (13.0) | 60 (31.4) |
| Microalbuminuria | 12 (12.0) | 57 (29.8) |
| Gross proteinuria | 2 (2.0) | 7 (3.7) |
| End-stage renal disease | 1 (1.0) | 1 (0.5) |
| Retinopathy complications | 15 (15.0) | 27 (14.1) |
| Background diabetic retinopathy | 13 (13.0) | 22 (11.5) |
| Proliferative diabetic retinopathy | 3 (3.0) | 5 (2.6) |
| Severe vision loss | 0 (0.0) | 1 (0.5) |
| Foot ulcer Complications | 2 (2.0) | 5 (2.6) |
| Uninfected ulcer | 0 (0.0) | 1 (0.5) |
| Infected ulcer | 0 (0.0) | 1 (0.5) |
| Healed ulcer | 2 (2.0) | 4 (2.1) |
| Amputation | 0 (0.0) | 1 (0.5) |
| Cataract | 10 (10.0) | 30 (15.7) |
| Macular oedema | 5 (5.0) | 5 (2.6) |
| Neuropathy | 17 (17.0) | 35 (18.3) |
| Depression | 23 (23.0) | 35 (18.3) |
CVD, cardiovascular disease.